# Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Source: https://onco.cc/trials/nct00769379/  
OnCo record `nct00769379` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab and Trastuzumab biosimilars in Ductal carcinoma in situ, run by National Cancer Institute (NCI), completed.

## Summary

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy is a phase 3 interventional study registered as NCT00769379 by National Cancer Institute (NCI), with 2014 participants recorded, started 2008-12-10 and reaching its primary completion in 2019-12-31. Interventions recorded: Laboratory Biomarker Analysis, Trastuzumab, Whole Breast Irradiation. Conditions recorded: Breast Ductal Carcinoma In Situ.

Linked to the drug Trastuzumab biosimilars because the registry names it among its interventions and Ductal carcinoma in situ among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00769379
- Phase: 3
- Setting: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 2014

## Sources

- ClinicalTrials.gov NCT00769379: https://clinicaltrials.gov/study/NCT00769379

## Connected records

- cancers: [Ductal carcinoma in situ (DCIS)](https://onco.cc/cancers/ductal-carcinoma-in-situ/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab biosimilars](https://onco.cc/drugs/trastuzumab-biosimilars/)

---
JSON: https://onco.cc/api/v1/entities/nct00769379.json